Outline of Survey on Long-Term Use of ORENCIA Intravenous Infusion 250mg

Trial Profile

Outline of Survey on Long-Term Use of ORENCIA Intravenous Infusion 250mg

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 14 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top